CurrentMedical Mutual - OhioPolicy AHS - M2141

Testing of Homocysteine Metabolism-Related Conditions

Coverage policy for laboratory testing used to detect and monitor homocystinuria and related homocysteine/metabolic disorders, including newborn screening, diagnostic plasma/dried blood spot testing, and monitoring of confirmed CBS deficiency; applies to providers submitting claims to Medical Mutual - Ohio.

Policy Summary

PayerMedical Mutual - Ohio

PolicyTesting of Homocysteine Metabolism-Related Conditions

Policy CodePolicy AHS - M2141

Change TypeReferences updatedcoverage criteria unchanged

Effective DateJun 1, 2026

Next Review DateJun 1, 2026

Key ActionVerify member benefits and applicable prior authorization/billing rules before ordering tHcy or related tests.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CoveredNewborn screening coverage

CoveredPlasma tHcy testing

<15 µmol/LNormal tHcy

>50 µmol/LNeonate tHcy

>100 µmol/LUntreated older tHcy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

inv-01: Covered Indications

Covered when any of the following apply:

Newborn screening for homocysteine-related conditions meets coverage criteria when any of the following are performed: (a) screening for classic homocystinuria due to CBS deficiency by quantitative plasma amino acids analysis and/or plasma or urine total homocysteine analysis; (b) screening for homocystinuria in dried blood spots; (c) screening for hypermethioninemia in dried blood spots.

[[chunk 3]]

Follow-up after elevated methionine: When the initial newborn screening test result exceeds the methionine cutoff, a repeat dried blood specimen submitted to the newborn screening program OR a quantitative plasma amino acid analysis plus plasma total homocysteine analysis meets coverage criteria.

[[chunk 3]]

Adults with suspected or confirmed CBS deficiency: For individuals over 18 years of age with homocystinuria suspected to be caused by CBS deficiency, and for monitoring therapy in those with confirmed CBS deficiency, total homocysteine testing in plasma meets coverage criteria.

[[chunk 3]]

inv-02: Guideline-based coverage and testing recommendations

Guideline-based testing recommendations cited in policy

Frontline testing for suspected remethylation/CBS disorders: Measure plasma total homocysteine (tHcy) as the frontline test in any patient presenting with relevant neurological, visual, hematological findings, subacute spinal cord degeneration, atypical hemolytic uremic syndrome, or unexplained vascular thrombosis; process blood for tHcy promptly (centrifuge within an hour and keep at 4°C or frozen) and use immunoassays or chromatographic methods as appropriate.

E-HOD strong recommendation; quality moderate

Newborn screening strategy: Use methionine and methionine-to-phenylalanine (Met/Phe) ratio in dried blood spots as first-tier newborn screening; analyze total homocysteine (tHcy) as a second-tier marker to increase specificity and consider Met/tHcy ratio where indicated.

E-HOD recommendation; specificity increased by tHcy second-tier

Confirmatory testing for CBS deficiency: Confirm suspected CBS deficiency by measuring cystathionine synthase activity in fibroblasts or plasma and/or by CBS gene mutation analysis; if one method is non-diagnostic, perform the other. The gold standard is determination of cystathionine production in cultured fibroblasts.

Analytical comparisons in the literature indicate that plasma assays generally perform better than dried blood spot (DBS) methods for methylmalonic acid (MMA) and total homocysteine (tHcy), although DBS tHcy may offer advantages for specimen stability. A UPLC‑MS/MS comparison found strong correlation between plasma and DBS tHcy measurements and concluded DBS can be an acceptable alternative when plasma processing is not feasible, but overall analytical performance favored plasma testing. Clinical workflows should favor plasma tHcy when available, with DBS reserved for settings where prompt plasma processing is not possible.

The policy editorial changes removed the pyridoxine (vitamin B6) challenge test from the laboratory coverage scope because it is classified as a medical procedure rather than a laboratory test. The revision explicitly removed the prior coverage statement and the associated CPT code (84207) from the laboratory policy; providers seeking pyridoxine challenge testing should pursue it as a clinical/medical procedure outside the laboratory test coverage rules.

Guideline guidance from E‑HOD strongly recommends measuring total homocysteine (tHcy) in blood rather than measuring free homocysteine. Total homocysteine is the recommended frontline laboratory measurement for suspected remethylation and CBS deficiency and already includes free and bound forms of homocysteine, making separate free Hcy testing unnecessary.

Measurement of free homocysteine is discouraged because it is detectable only at relatively high tHcy concentrations and is reported to have poor sensitivity and limited reproducibility; therefore it is not recommended as a substitute for total homocysteine testing.

Covered Indications and Use Cases

inv-24: Newborn screening for classic homocystinuria (CBS deficiency) and screening for hypermethioninemia; use of Met/Phe ratio as first-tier with tHcy as second-tier

Newborn screening strategies and covered newborn indications

First-tier newborn screening: Use methionine measurement and the methionine-to-phenylalanine (Met/Phe) ratio in dried blood spots as first-tier newborn screening for homocystinurias and hypermethioninemia.

E-HOD and ACMG recommend Met and Met/Phe first-tier ([[chunk 18]])

Second-tier newborn testing: If first-tier screening is abnormal or to improve specificity, perform total homocysteine (tHcy) measurement as a second-tier test on dried blood spot or plasma, and consider calculating Met/tHcy ratio.

tHcy as second-tier increases specificity ([[chunk 18]])

Follow-up diagnostic steps after abnormal newborn screen: When initial newborn screening exceeds the methionine cutoff, either submit a repeat dried blood specimen to the newborn screening program OR perform quantitative plasma amino acid analysis plus plasma total homocysteine analysis.

Coding and Diagnostic Thresholds

Applicable CPT/HCPCS Procedure Codesmixed

No codes listed

Applicable CPT/HCPCS Procedure CodesCPT

82136	Amino acids, 2 to 5 amino acids, quantitative, each specimen.
82139	Amino acids, 6 or more amino acids, quantitative, each specimen.
82615	Cystine and homocysteine, urine, qualitative.
83090	Homocysteine.
83921	Organic acid, single, quantitative

inv-09: tHcy diagnostic thresholds

Neonatal diagnostic threshold>50 µmol/L (neonate with homocystinuria)

Untreated older individual diagnostic threshold>100 µmol/L (untreated older individual with homocystinuria)

Normal control value<15 µmol/L (control)

inv-10: Target total plasma homocysteine

Target for pyridoxine-responsive patientsTotal plasma homocysteine <50 µmol/L

Target for pyridoxine-unresponsive patients (free Hcy equivalent)Approximately 120 µmol/L total homocysteine (corresponding to <11 µmol/L free homocysteine)

Provider Actions and Billing Notes

Prior Authorization

Benefit verification required

Verify member benefits and any applicable requirements (including prior authorization, coverage limits, and medical necessity criteria) before submitting testing requests. Coverage is benefit-dependent — coverage determinations are made based on the individual's plan at the time of service; Medicare and Medicaid members are subject to applicable government rules.

Benefit verification required at time of request
Medicare/Medicaid per applicable regulations

Billing Rule

Procedure codes and payer review

Providers should follow payer billing and prior authorization processes for the CPT/HCPCS codes associated with homocysteine and related testing. Confirm coding and medical necessity with the payer; some codes may require additional documentation.

Ordering and Specimen Requirements

Note

Ordering: follow specimen handling and pre-treatment sampling guidance

No specific ordering-provider restrictions are stated in this policy; however, ensure proper specimen handling and pre-treatment sampling per guidance when ordering tHcy and related tests.

Ensure plasma/urine samples for confirmatory testing are obtained before treatment when indicated
Follow prompt processing and cold-chain requirements for tHcy specimens

Documentation Required

tHcy pre-analytic handling: centrifuge quickly and keep cold or frozen

For total homocysteine testing, centrifuge the blood sample within one hour of collection and keep the plasma at 4°C or frozen until analysis; immunoassays or chromatographic methods are acceptable for tHcy measurement.

Centrifuge within one hour
Store at 4°C or freeze until analysis
Use validated immunoassay or chromatographic methods

Frequency and Monitoring Limits

inv-28: Not specified in this partial document — frequency limits placeholder

Frequency limits (document portion)Not specified in this partial document; see local benefit for limits

Use caseApplies to newborn screening, diagnostic and monitoring tests when covered per criteria

ActionVerify frequency limits with payer or full policy for test-specific rules

inv-29: tHcy, amino acids, folate, vitamin B12 — monitoring frequency individualized

Monitoring frequencyIndividualized on a case-by-case basis (depends on severity, treatment plan, age)

Tests to monitorTotal homocysteine (tHcy), plasma amino acids, folate, and vitamin B12

Not Covered / Exclusions

Free homocysteine testing in place of total homocysteine (tHcy) is not recommended. E‑HOD issues a strong recommendation against measuring free homocysteine as a replacement for tHcy because free Hcy lacks sensitivity and reproducibility compared with total plasma homocysteine.

The pyridoxine (B6) challenge test has been removed from the laboratory policy because it is considered a medical procedure rather than a laboratory test. This change eliminates the prior laboratory coverage statement for the pyridoxine challenge and removes CPT code 84207 from the policy's procedure code list; providers should classify this evaluation as a clinical/medical procedure outside the laboratory testing coverage rules.

Background

Homocystinuria is an inherited metabolic disorder most commonly caused by deficiency of cystathionine β‑synthase (CBS). Classic CBS deficiency produces markedly elevated total homocysteine (tHcy) and often increased methionine (Met). Typical diagnostic biochemical features are tHcy <15 µmol/L in controls, neonates with homocystinuria often >50 µmol/L, and untreated older individuals frequently >100 µmol/L. Measurement of plasma tHcy is the frontline laboratory test for diagnosis and monitoring; when tHcy is elevated, additional pre‑treatment testing (plasma and urine methylmalonic acid, plasma methionine, folate and vitamin B12) should be obtained and plasma processing should occur promptly to preserve specimen integrity.

Definitions

inv-20: tHcy — Total homocysteine (plasma)

Test nameTotal homocysteine (tHcy) — plasma

Specimen typePlasma (preferred); dried blood spot acceptable if plasma processing not possible

Processing notesCentrifuge blood for tHcy within an hour and keep at 4°C or frozen until analysis; immunoassays or chromatographic methods are suitable

IndicationsFrontline laboratory measurement for suspected remethylation disorders and CBS deficiency; used in newborn screening algorithms as second-tier marker

inv-21: CBS — Cystathionine β-synthase

DefinitionCBS = Cystathionine β-synthase

Policy Summary

PayerMedical Mutual - Ohio

PolicyTesting of Homocysteine Metabolism-Related Conditions

Policy CodePolicy AHS - M2141

Change TypeReferences updatedcoverage criteria unchanged

Effective DateJun 1, 2026

Next Review DateJun 1, 2026

Key ActionVerify member benefits and applicable prior authorization/billing rules before ordering tHcy or related tests.

SourceLink

On This Page

Grade B-C; gold standard: cultured fibroblasts

Pre-analytic and additional testing before treatment: If total homocysteine is elevated, obtain plasma and urine samples for methylmalonic acid (MMA), methionine, folate and vitamin B12 before initiating treatment; ensure proper specimen handling (centrifuge tHcy blood within an hour and keep cold or frozen until analysis).

E-HOD recommendations

Monitoring during therapy: During therapy monitor tHcy, amino acids, folate and vitamin B12; monitoring frequency should be individualized and target tHcy ranges depend on pyridoxine responsiveness.tHcy <50 µmol/L (pyridoxine-responsive); ~120 µmol/L total tHcy (pyridoxine-unresponsive)

Targets proposed by E-HOD/Morris et al.

Covered follow-up per policy ([[chunk 3]])

inv-25: Diagnostic testing for suspected remethylation disorders or CBS deficiency — prompt plasma tHcy and pre-treatment specimens

Diagnostic testing for suspected disorders — prompt testing and pre-treatment specimen collection

Frontline diagnostic test: Measure plasma total homocysteine (tHcy) promptly in any patient with clinical features suggestive of remethylation disorders or CBS deficiency; tHcy is the recommended frontline laboratory measurement.

E-HOD strong recommendation; policy references ([[chunk 19]], [[chunk 3]])

Pre-treatment specimen collection: If tHcy is elevated, obtain plasma and urine samples for methylmalonic acid (MMA), methionine, folate and vitamin B12 BEFORE initiating treatment.

Ensure samples collected prior to therapy per guidelines ([[chunk 19]])

Specimen handling: Process blood for tHcy by centrifuging within one hour and keep the specimen at 4°C or frozen until analysis; immunoassays or chromatographic methods are acceptable.

Pre-analytic handling recommended ([[chunk 19]])

inv-26: Monitoring therapy in confirmed CBS deficiency — plasma total homocysteine testing meets coverage criteria for monitoring in adults

Monitoring criteria for confirmed CBS deficiency in adults

Monitoring test covered: Plasma total homocysteine (tHcy) testing meets coverage criteria for monitoring therapy in adults with confirmed CBS deficiency.

Policy states plasma tHcy testing meets coverage criteria for adults ([[chunk 3]])

Monitoring targets and interpretation: Target tHcy levels depend on pyridoxine responsiveness: aim for tHcy <50 µmol/L in pyridoxine-responsive patients; pyridoxine-unresponsive patients may have target total tHcy around ~120 µmol/L (corresponding to expected clinical guidance).tHcy <50 µmol/L (responsive); ~120 µmol/L (unresponsive)

Target ranges referenced in guidelines and clinical utility ([[chunk 21]], [[chunk 12]])

inv-27: Suspected remethylation disorders and CBS deficiency; newborn screening recommendations — tHcy frontline; Met/Met:Phe first-tier with tHcy second-tier

Recommended frontline testing and newborn screening approach for suspected remethylation disorders and CBS deficiency

Frontline test for suspected remethylation disorders: For suspected remethylation disorders (cblC, cblD, cblE, cblF, cblG, cblJ, MTHFR deficiency) and CBS deficiency, measure plasma total homocysteine (tHcy) as the frontline diagnostic test.

E-HOD recommendations ([[chunk 19]])

Newborn screening algorithm: In newborn screening programs, use Methionine (Met) and Met/Phe ratio as first-tier dried blood spot tests and apply tHcy as a second-tier marker to improve specificity; consider Met/tHcy ratio where indicated.

E-HOD guidance ([[chunk 18]], [[chunk 20]])

Confirmatory testing guidance: Confirm CBS deficiency using enzyme activity (cystathionine synthase) in fibroblasts or plasma and/or CBS gene mutation analysis; perform alternate method if one is non-diagnostic.

Gold standard described by E-HOD ([[chunk 20]])

Monitoring recommendation contextTargets proposed by E-HOD and applied during individualized monitoring of therapy

Relevant CPT codes: 82136, 82139, 82615, 83090, 83921
Procedure codes listed are for reference — follow payer-specific billing rules and authorization processes

Note

Government policy precedence

If a conflict exists between this policy and any applicable government policy (e.g., LCD, NCD, or state Medicaid), the government policy will take precedence and will be used to make coverage determinations.

Government (LCD/NCD/state Medicaid) policy supersedes when in conflict
Check CMS and state Medicaid sites for current guidance

Documentation Required

Specimen handling and pre-treatment testing

When total homocysteine (tHcy) is elevated, obtain plasma and urine samples for MMA, methionine, folate, and vitamin B12 prior to initiating treatment. These pre-treatment tests support differential diagnosis between remethylation disorders and CBS deficiency and are recommended by guideline bodies.

Obtain plasma and urine MMA, methionine, folate, and vitamin B12 before treatment when tHcy is high
Use tHcy and Met measurements together to help distinguish CBS deficiency from other disorders

Documentation Required

Pre-analytic and pre-treatment sampling

Collect and handle samples per guideline recommendations to ensure valid tHcy results: centrifuge blood specimens within one hour of collection and keep them refrigerated (about 4°C) or freeze until analysis; maintain cold chain during transport. Use total homocysteine assays (immunoassay or chromatographic methods); do not substitute free homocysteine.

Centrifuge within one hour and keep samples at 4°C or frozen until analysis
Use immunoassays or chromatographic methods for tHcy; do not measure free homocysteine instead of total homocysteine
Dried blood spot tHcy measurement acceptable if plasma processing is not possible

Prior Authorization

Benefit-dependent coverage

Coverage is dependent on the member's benefit at the time of request; verify eligibility, plan exclusions, and any program-specific rules (Medicare/Medicaid) prior to testing.

Benefit-dependent coverage — confirm member benefits at time of request
Medicare/Medicaid governed by applicable LCD/NCD and state Medicaid rules

Clinical contextMonitoring recommended in all patients during therapy per E‑HOD guidance

Enzyme implicated in classic homocystinuria when deficient

Confirmation contextCBS analysis used in conjunction with tHcy and amino acid testing for diagnosis

inv-22: total homocysteine (tHcy) — recommended frontline laboratory measurement and processing notes

Recommended frontline measurementTotal homocysteine (tHcy) in blood (plasma) is the frontline laboratory test for suspected remethylation and CBS deficiency

Processing and handlingCentrifuge blood within one hour; keep at 4°C or freeze until analysis to preserve stability

Analytic methodsImmunoassays or chromatographic methods (e.g., LC-MS/MS) are suitable for tHcy measurement

inv-23: CBS deficiency confirmation — confirmatory testing by enzyme activity or gene mutation analysis

Confirmation methodsConfirm CBS deficiency by measuring cystathionine synthase activity in fibroblasts or plasma and/or by CBS gene mutation analysis

Gold standardDetermination of cystathionine production from homocysteine and serine in cultured fibroblasts is the gold standard

Approach if one test non-diagnosticIf one method (enzyme or DNA) does not confirm diagnosis, perform the other method